Skip to main content

Gastrointestinal Diseases

Gastroenterology
4
Pipeline Programs
14
Companies
14
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 17 programs with unclassified modality

Gastroenterology is a $7.3B market characterized by mature, blockbuster-driven portfolios with near-term patent cliff risks.

$7.3B marketMature→ Stable30 products15 companies

Key Trends

  • AbbVie dominance with 43% of top-10 product spending (LINZESS, CREON, RINVOQ)
  • Guanylate cyclase activators and JAK inhibitors driving innovation in constipation and IBD
  • Multiple patent expirations 2026–2030 creating biosimilar and generic erosion headwinds

Career Verdict

Gastroenterology offers stable, well-compensated roles but limited growth upside; best for risk-averse professionals seeking established markets over innovation-driven career trajectories.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1LINZESSStable
$1.8B
AbbVie·Peak7.7yr
#2CREONDeclining
$1.5B
AbbVie·LOE Approaching
#3XIFAXANDeclining
$1.1B
Bausch Health·LOE Approaching
#4RINVOQGrowing
$976M
AbbVie·Peak11.8yr
#5XELJANZ XRStable
$586M
Pfizer·Peak8.3yr

Drug Class Breakdown

Unknown Mechanism
$2.5B(34%)

mature portfolio anchor

Guanylate Cyclase Activators
$1.9B(27%)

well-established class

Pancreatic Enzymes
$1.5B(20%)

facing biosimilar competition

Janus Kinase Inhibitors
$976M(13%)

growing IBD adoption

Proton Pump Inhibitors
$107M(1%)

commoditized

Career Outlook

Stable

Gastroenterology is a stable, mature market anchored by blockbusters with long patent runways (LINZESS to 2034, RINVOQ to 2038) but faces near-term erosion (XELJANZ 2026). Employment growth is modest and concentrated in device/diagnostic firms rather than pure-pharma. Best for professionals seeking predictable revenue streams over high-risk innovation bets.

Breaking In

Target roles at Roche, J&J, or diagnostic-adjacent firms to maximize hiring volume; pure pharma gastro entry points at AbbVie/Pfizer are limited and highly competitive.

For Experienced Professionals

Leverage gastro expertise in broader GI/immunology roles (Takeda, Novartis) or transition to medical devices/diagnostics where hiring is 3x higher than pharma.

In-Demand Skills

IBD and IBS indication expertiseJAK inhibitor pharmacologyMedical device integration (diagnostics, endoscopy)Generic/biosimilar launch readinessReal-world evidence generation

Best For

Medical Science Liaison (IBD/IBS focus)Commercial Manager (Generic Launch)Clinical Operations SpecialistMarket Access/Reimbursement StrategistRegulatory Affairs (small molecule focus)

Hiring Landscape

$70K-$213K

Total hiring across the gastro ecosystem is 1,818 jobs, dominated by engineering (434) and commercial roles (269). Roche leads absolute hiring at 377 roles, followed by Johnson & Johnson (323) and GE HealthCare (293), reflecting broad medical device and diagnostic involvement alongside pharma. AbbVie's gastro-specific hiring (78 jobs) is modest relative to its portfolio dominance.

1,818
Open Roles
4
Companies Hiring
3
Departments

Top Hiring Companies

377Growing
293Stable
78Stable

By Department

Engineering(24%)
$169K
Commercial(15%)
$176K
Manufacturing(10%)
$213K

Manufacturing and commercial roles command premium salaries ($213K and $176K respectively), but total gastro-pharma hiring is concentrated in Roche and J&J, not pure-play GI companies.

Competitive Landscape

14 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
2
IDIAZOLE 20mg DR tabsPhase 4
Idiazole 20mg DR tabsPhase 4
Evaluation of Universal Rotavirus Vaccination ProgramN/A
Norgine
NorgineAustria - Vienna
1 program
1
MOVIPREPPhase 41 trial
Active Trials
NCT00605228Completed400Est. Dec 2007
Abbott
AbbottABBOTT PARK, IL
1 program
1
Peptide based enteral formulaPhase 3Peptide1 trial
Active Trials
NCT01191112Completed27Est. Nov 2011
GSK
GSKLONDON, United Kingdom
3 programs
Evaluation of Universal Rotavirus Vaccination ProgramN/A1 trial
IDIAZOLE 20mg DR tabsPHASE_41 trial
Idiazole 20mg DR tabsPHASE_41 trial
Active Trials
NCT01273077Completed12,705Est. Jul 2013
NCT02605395Completed70Est. Mar 2014
NCT02446483Completed60Est. Mar 2014
Hamilton medical
Hamilton medicalSwitzerland - Bonaduz
1 program
Abdominal Drainage Fluid CollectionN/A1 trial
Active Trials
NCT06541431Recruiting50Est. Jul 2025
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Correlation of Toxins With Gastrointestinal (GI) and Overall HealthN/A1 trial
Active Trials
NCT06278311Not Yet Recruiting250Est. Jan 2026
Labcorp
LabcorpBURLINGTON, NC
1 program
Correlation of Toxins With Gastrointestinal (GI) and Overall HealthN/A
Innovation Pharmaceuticals
1 program
Endoscopy exploratory single armN/A1 trial
Active Trials
NCT02143284Completed30Est. Jan 2015
G-Tech Medical
G-Tech MedicalCA - Mountain View
1 program
G-Tech Wireless Patch SystemN/A1 trial
Active Trials
NCT05712525Unknown150Est. Oct 2024
Motus GI
Motus GIFL - Fort Lauderdale
1 program
Pure-Vu SystemN/A1 trial
Active Trials
NCT03493009Withdrawn0Est. May 2018
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Symptoms and Endoscopic Results in Consideration of PretreatmentN/A1 trial
Active Trials
NCT00612404Completed16,255
Philips
PhilipsNetherlands - Amsterdam
1 program
XperGuideN/A1 trial
Active Trials
NCT02021071Completed24Est. Jun 2014
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Buscopan® plusPHASE_21 trial
Active Trials
NCT02229786Completed1,637
Sanofi
SanofiPARIS, France
1 program
Bacillus clausiiPHASE_41 trial
Active Trials
NCT00424905Completed60

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKIDIAZOLE 20mg DR tabs
GSKIdiazole 20mg DR tabs
NorgineMOVIPREP
SanofiBacillus clausii
AbbottPeptide based enteral formula
Boehringer IngelheimBuscopan® plus
Angeles TherapeuticsCorrelation of Toxins With Gastrointestinal (GI) and Overall Health
Hamilton medicalAbdominal Drainage Fluid Collection
G-Tech MedicalG-Tech Wireless Patch System
Motus GIPure-Vu System
Innovation PharmaceuticalsEndoscopy exploratory single arm
PhilipsXperGuide
GSKEvaluation of Universal Rotavirus Vaccination Program
AstraZenecaSymptoms and Endoscopic Results in Consideration of Pretreatment

Clinical Trials (14)

Total enrollment: 31,718 patients across 14 trials

NCT02605395GSKIDIAZOLE 20mg DR tabs

Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions

Start: Mar 2014Est. completion: Mar 201470 patients
Phase 4Completed
NCT02446483GSKIdiazole 20mg DR tabs

A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults

Start: Mar 2014Est. completion: Mar 201460 patients
Phase 4Completed

A Phase IV Study, of the Efficacy, Safety, and Acceptability of Moviprep® Versus Colopeg® in Colonoscopy Preparation

Start: May 2007Est. completion: Dec 2007400 patients
Phase 4Completed
NCT00424905SanofiBacillus clausii

DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect

Start: Dec 200660 patients
Phase 4Completed
NCT01191112AbbottPeptide based enteral formula

Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population

Start: Jan 2011Est. completion: Nov 201127 patients
Phase 3Completed

Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms

Start: Feb 19981,637 patients
Phase 2Completed
NCT06278311Angeles TherapeuticsCorrelation of Toxins With Gastrointestinal (GI) and Overall Health

Correlation of Toxins With Gastrointestinal (GI) and Overall Health

Start: Feb 2025Est. completion: Jan 2026250 patients
N/ANot Yet Recruiting
NCT06541431Hamilton medicalAbdominal Drainage Fluid Collection

Analytical Validation of Stream™ Platform

Start: Nov 2024Est. completion: Jul 202550 patients
N/ARecruiting
NCT05712525G-Tech MedicalG-Tech Wireless Patch System

Gut Recovery In Patients Following Surgery

Start: Oct 2022Est. completion: Oct 2024150 patients
N/AUnknown
NCT03493009Motus GIPure-Vu System

Optimizing the Preparation Regime Prior to Colonoscopy Procedure With Pure-Vu System

Start: May 2018Est. completion: May 20180
N/AWithdrawn
NCT02143284Innovation PharmaceuticalsEndoscopy exploratory single arm

A Study of EndoChoice's Upper&Lower Endoscopic Systems Utilizing a Full Spectrum Optical Technology

Start: May 2014Est. completion: Jan 201530 patients
N/ACompleted

Virtual Path Planning for Image-guided Needle Interventions

Start: Dec 2013Est. completion: Jun 201424 patients
N/ACompleted
NCT01273077GSKEvaluation of Universal Rotavirus Vaccination Program

Evaluation of Universal Rotavirus Vaccination Program

Start: Dec 2010Est. completion: Jul 201312,705 patients
N/ACompleted
NCT00612404AstraZenecaSymptoms and Endoscopic Results in Consideration of Pretreatment

Symptoms and Endoscopic Results in Consideration of Pretreatment

Start: Sep 200516,255 patients
N/ACompleted

Related Jobs in Gastroenterology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 31,718 patients
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.